Article PDF
References
Tang R, Shields J, Schiffman J, Li H, Locher D, Hampton J, et al. Retinal changes associated with tamoxifen treatment for breast cancer. Eye 1997;11:295–7.
Ashford AR, Donev I, Tiwari RP, Garrett TJ . Reversible ocular toxicity related to tamoxifen therapy. Cancer 1988;61:33–5.
Vinding T, Nielsen NV . Retinopathy caused by treatment with tamoxifen in low dosage. Acta Ophthalmol (Copenh) 1983;61:45–50.
Griffiths MFP . Tamoxifen retinopathy at low dosage [letter]. Am J Ophthalmol 1987;104:185–6.
Gerner EW . Ocular toxicity of tamoxifen. Ann Ophthalmol 1989;21:420–3.
Jordan VC . Tamoxifen: a guide for clinicians and patients. New York: PRR, 1996.
Swedish Breast Cancer Cooperative Group. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 1996;88:1543–9.
Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996;88:1529–42.
Tormey DC, Gray R, Falkson HC, for the Eastern Cooperative Oncology Group. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. J Natl Cancer Inst 1996;88:1828–33.
British national formulary. London: BMA/Royal Pharmaceutical Society of Great Britain, 1998;35:385–6.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Murray, D., Gibson, J. Letter. Eye 12, 485–486 (1998). https://doi.org/10.1038/eye.1998.114
Issue Date:
DOI: https://doi.org/10.1038/eye.1998.114